- Home
- FGI vs GLTO Comparison
FGI vs GLTO Comparison
Compare FGI & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGI
- GLTO
- Stock Information
- Founded
- FGI 1987
- GLTO 2011
- Country
- FGI United States
- GLTO Denmark
- Employees
- FGI N/A
- GLTO N/A
- Industry
- FGI Industrial Specialties
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- FGI Industrials
- GLTO Health Care
- Exchange
- FGI Nasdaq
- GLTO Nasdaq
- Market Cap
- FGI 5.5M
- GLTO 4.5M
- IPO Year
- FGI 2022
- GLTO 2020
- Fundamental
- Price
- FGI $0.66
- GLTO $3.91
- Analyst Decision
- FGI
- GLTO Buy
- Analyst Count
- FGI 0
- GLTO 1
- Target Price
- FGI N/A
- GLTO $10.00
- AVG Volume (30 Days)
- FGI 167.0K
- GLTO 15.7K
- Earning Date
- FGI 08-06-2025
- GLTO 08-11-2025
- Dividend Yield
- FGI N/A
- GLTO N/A
- EPS Growth
- FGI N/A
- GLTO N/A
- EPS
- FGI N/A
- GLTO N/A
- Revenue
- FGI $134,277,102.00
- GLTO N/A
- Revenue This Year
- FGI $7.72
- GLTO N/A
- Revenue Next Year
- FGI $6.94
- GLTO N/A
- P/E Ratio
- FGI N/A
- GLTO N/A
- Revenue Growth
- FGI 11.13
- GLTO N/A
- 52 Week Low
- FGI $0.46
- GLTO $2.01
- 52 Week High
- FGI $1.20
- GLTO $16.07
- Technical
- Relative Strength Index (RSI)
- FGI 48.82
- GLTO 59.96
- Support Level
- FGI $0.64
- GLTO $3.32
- Resistance Level
- FGI $0.67
- GLTO $3.61
- Average True Range (ATR)
- FGI 0.09
- GLTO 0.22
- MACD
- FGI 0.00
- GLTO -0.01
- Stochastic Oscillator
- FGI 29.03
- GLTO 79.09
About FGI FGI Industries Ltd.
FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.